Delivery Order SPE2DB24D2205-SPE2DB25FEHEH
- Not listed
- The Defense Logistics Agency awarded a $1,396.85 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed price delivery order, issued on July 24, 2025, with an ultimate completion date of August 14, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The award, issued on August 21, 2025, with an ultimate completion date of September 12, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on March 18, 2025, is scheduled for completion by April 8, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation,...
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes, with a ceiling value of $11,174.80. The contract, awarded on June 26, 2025, with an ultimate completion date of July 18, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes, valued at $8,381.10. Issued on August 18, 2025, with an ultimate completion date of September 9, 2025, this firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,352.44 for 100-unit vials of Xeomin, a botulinum toxin injection used primarily for treating muscle spasticity and other neurological conditions. This non-competitive, firm fixed-price delivery order was awarded on July 22, 2025, with an ultimate completion date of August 12, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic applications in military and veteran healthcare settings. This firm fixed-price delivery order, valued at $2,514.33, was competitively awarded without set-aside provisions and is scheduled for completion by September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performance...
- The Defense Logistics Agency awarded a $11,174.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This non-set-aside competitive award was issued on September 5, 2025, with an ultimate completion date of September 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHEHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,234.96 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. This firm fixed-price delivery order, issued on September 5, 2025, with completion targeted for September 26, 2025, is being fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award utilizes no set-aside designation, indicating it was competitively awarded under open competition. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp supplies a wide range of medications, vaccines, and medical supplies to support military healthcare systems and other government agencies including the Defense Health Agency and U.S. Coast Guard. The company's substantial IDC reflects its established capability to meet federal pharmaceutical procurement requirements across multiple therapeutic domains on a global basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 9/5/25 |